SUPERNUS PHARMACEUTICALS, INC. 8-K

What Happened
Supernus Pharmaceuticals, Inc. announced its financial results for the fourth quarter ended December 31, 2025 in a press release dated February 24, 2026. The press release was furnished as Exhibit 99.1 to a Form 8-K (Item 2.02). The company is hosting a conference call to discuss the results on Tuesday, February 24, 2026 at 4:30 p.m. Eastern; a live webcast is available at www.supernus.com and will be archived on the company website for 60 days.

Key Details

• Press release reporting Q4 2025 results furnished as Exhibit 99.1 to the Form 8-K (filed Feb 24, 2026).
• Quarter covered: ended December 31, 2025.
• Conference call: Feb 24, 2026 at 4:30 p.m. ET; live webcast at www.supernus.com; archived for 60 days.
• Information in Item 2.02 is “furnished” (not “filed”) and the filing includes forward-looking statements subject to risks described in the company’s Form 10-K for the year ended Dec 31, 2024 (filed Feb 25, 2025).

Why It Matters
This 8-K signals the company has released its quarterly earnings and set a management call where investors can hear details and ask questions about revenue, profitability, guidance, and operating trends. Because the press release is furnished (not filed), it is included for disclosure but is not subject to the same Section 18 liability as filed statements. Investors should review the press release, listen to the webcast for management commentary, and consider the company’s disclosed risk factors when assessing the results.